We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




First Blood-Based Test Measures Key Alzheimer's Biomarker in Asymptomatic and Symptomatic Individuals

By LabMedica International staff writers
Posted on 30 Jul 2025

Alzheimer’s disease (AD), the sixth leading cause of death in the United States, affects an estimated 7. More...

2 million Americans aged 65 or older. Current diagnostic methods for AD are often invasive, expensive, and typically only effective in the later stages of the disease, limiting opportunities for early intervention. A significant challenge has been the absence of a clinically available blood test capable of accurately predicting the presence of tau aggregates in the brain before the onset of clinical symptoms. Now, new research has demonstrated that a novel assay accurately measures active tau pathology—a key biomarker of AD and other tauopathies—in individuals with and without cognitive impairment.

The VeraBIND Tau Assay, developed by Veravas Inc. (Austin, TX, USA), is the first blood-based test designed to measure the pathological binding activity between hyperphosphorylated tau and normal tau, a hallmark of AD and other tauopathies. Unlike existing tests that merely quantify biomarker levels, VeraBIND Tau detects the active spread of tau proteins, providing a more direct indication of disease progression. The assay detects tau pathology in adult patients aged 50 years and older, and produces results consistent with tau positron emission tomography (Tau-PET) brain scans. Two independent analyses presented at the 2025 Alzheimer’s Association International Conference validated the effectiveness of VeraBIND Tau.

One analysis demonstrated over 95% sensitivity and specificity in distinguishing amyloid-positive and tau-positive individuals from amyloid-negative and tau-negative cases, with accuracy observed in both cognitively unimpaired and impaired individuals. The second analysis confirmed the assay’s ability to correctly identify Tau-PET-positive individuals regardless of amyloid status, and found that those with positive results scored lower on cognitive assessments. The data also showed that the assay is highly sensitive to early stages of tau aggregation, unlike current plasma tau methods that are more effective only at later disease stages. Veravas plans to continue supporting researchers, clinicians, and industry with this breakthrough technology to aid in early diagnosis, treatment planning, and clinical trial recruitment.

"This breakthrough technology can also support industry in expediting clinical trial recruitment and lessening trial duration. We look forward to supporting industry, researchers, and healthcare providers to address a huge unmet need and provide a new source of hope to patients and their families," said John Forrest, Co-Founder, CEO & Executive Chairman of Veravas.

Related Links:
Veravas Inc


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Hematology Analyzer
Medonic M32B
New
Automatic Hematology Analyzer
DH-800 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Microbiology

view channel
Image: New diagnostics could predict a woman’s risk of a common sexually transmitted infection (Photo courtesy of 123RF)

New Markers Could Predict Risk of Severe Chlamydia Infection

Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more

Technology

view channel
Image: The sensor can help diagnose diabetes and prediabetes on-site in a few minutes using just a breath sample (Photo courtesy of Larry Cheng/Penn State)

Graphene-Based Sensor Uses Breath Sample to Identify Diabetes and Prediabetes in Minutes

About 37 million U.S. adults live with diabetes, and one in five is unaware of their condition. Diagnosing diabetes often requires blood draws or lab visits, which are costly and inconvenient.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.